Limsan, Irene Rose P.

HRN: 05-19-33  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/17/2022
METRONIDAZOLE 500MG (TAB)
06/17/2022
06/23/2022
PO
500mg
TID X 7 Days
WBC: 23.8; S/p NSVD, Transient Uterine Atony
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Reproductive Tract    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: